不同时间间隔的肝动脉化疗栓塞和射频消融联合治疗中晚期肝癌的预后分析

应希慧; 赖林强; 陈丽; 杨宏远; 纪建松; 涂建飞

doi:10.16766/j.cnki.issn.1674-4152.002496

不同时间间隔的肝动脉化疗栓塞和射频消融联合治疗中晚期肝癌的预后分析

doi: 10.16766/j.cnki.issn.1674-4152.002496

浙江省影像诊断与介入微创研究重点实验室，浙江大学丽水医院介入诊疗中心，浙江丽水 323000

基金项目:

浙江省医药卫生重大科技计划重点项目 WKJ-ZJ-1932

浙江省基础公益研究计划项目 LGF18H220001

浙江省医药卫生科技计划项目面上项目 2018KY933

浙江省医药卫生科技计划项目 2020ZH087

详细信息

通讯作者:
涂建飞, E-mail: jianfei1133@163.com

中图分类号: R735.7R730.58
计量
- 文章访问数: 151
- HTML全文浏览量: 69
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-02
- 网络出版日期: 2022-09-21

Prognostic analysis of hepatic arterial chemoembolization and radiofrequency ablation combination with different time intervals for patients with advanced hepatocellular carcinoma

Key Laboratory of Imaging Diagnosis and Minimally Invasive and Intervention Research of Zhejiang Province, Department of Radiology Lishui Hospital of Zhejiang University, Lishui, Zhejiang 323000, China

摘要

摘要: 目的探讨不同时间间隔肝动脉化疗栓塞术(TACE)联合射频消融(RFA)序贯治疗中晚期肝癌(HCC)的效果。方法回顾浙江大学丽水医院介入诊疗中心2012年2月—2017年12月99例HCC患者的临床资料，所有患者均接受了TACE和RFA序贯治疗。根据TACE和RFA的治疗间隔时间，将患者分为3组，分别为A组(0~5 d，30例)、B组(6~22 d，54例)和C组(＞22 d，15例)。使用递归分割法选择最合适的TACE-RFA间期阈值，主要研究终点为总生存期(OS)，次要研究终点为肿瘤无进展生存期(PFS)与治疗相关的不良事件。结果末次随访时间为2020年12月30日。分析结果显示较长的TACE-RFA时间间隔与较差的OS相关：A组vs. B组，P=0.694；A组vs. C组，P=0.037；B组vs. C组，P=0.023。C组15例患者中，73.3%(11/15)的患者死亡。3组中位OS分别为32.3、34.1和23.2个月。结论 TACE和RFA序贯时间间隔与患者预后有关，较短的时间间隔可以提高中晚期HCC患者的OS和PFS，但最佳的时间间隔仍需进一步大样本多中心临床研究确认。
- 肝细胞癌 /
- 化疗栓塞术 /
- 射频消融术 /
- 生存 /
- 疗效
Abstract: Objective To investigate the appropriate interval between transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) in treatment of advanced hepatocellular carcinoma (HCC). Methods The clinical data of 99 patients with HCC in Department of Radiology Lishui Hospital of Zhejiang University was retrospectively collected from February 2012 to December 2017. All patients received sequential treatment of TACE and RFA. The treatment interval of TACE and RFA was calculated, and the patients were divided into 3 subgroups: group A (0-5 days, n=30), group B (6-22 days, n=54), and Group C (>22 days, n=15). Recursive segmentation was used to select the most appropriate TACE-RFA interval threshold. The primary study endpoint was overall survival (OS), and the secondary study endpoint was tumor progression-free survival (PFS) and treatment-related adverse events. Results The last follow-up time was December 30, 2020. The data showed that longer TACE-RFA time intervals were associated with poor OS (group A vs. group B, P=0.694; group A vs. Group C, P=0.037; group B vs. group C, P=0.023). Among the 15 patients in group C, 73.3% (11/15) died. The median OS of the 3 subgroups were 32.3, 34.1, and 23.2 months, respectively. Conclusion The time interval between TACE and RFA is related to the prognosis of HCC patients. The shorter time intervals can improve OS and PFS in HCC patients. However, the optimal time interval still needs to be confirmed by large-scale multi-center clinical trials.
- Hepatocellular carcinoma /
- Chemoembolization /
- Radiofrequency ablation /
- Survival /
- Efficacy

HTML全文

图 1 3组中晚期HCC患者OS比较

Figure 1. Comparison of OS in three groups of patients with advanced HCC

下载: 全尺寸图片幻灯片

图 2 3组中晚期HCC患者PFS比较

Figure 2. Comparison of PFS in three groups of patients with advanced HCC

下载: 全尺寸图片幻灯片

图 3 去除转移相关因素后3组中晚期HCC患者OS比较

Figure 3. Comparison of OS in three groups of patients with advanced HCC after removal of metastasis related factors

下载: 全尺寸图片幻灯片

图 4 去除转移相关因素后3组中晚期HCC患者PFS比较

Figure 4. Comparison of PFS in three groups of patients with advanced HCC after removal of metastasis related factors

下载: 全尺寸图片幻灯片

表 1 3组中晚期HCC患者一般资料比较

Table 1. Comparison of general data of three groups in patients with advanced HCC

项目	A组(n=30)	B组(n=54)	C组(n=15)	统计量	P值
年龄(x±s, 岁)	57.7±12.5	55.9±10.5	57.2±10.4	0.275^a	0.764
性别[例(%)]				1.800^b	0.430
女性	2(6.7)	6(11.1)	3(20.0)
男性	28(93.3)	48(88.9)	12(80.0)
HBV(HBsAg)[例(%)]				0.463^b	0.407
阴性	1(3.3)	6(11.1)	1(6.7)
阳性	29(96.7)	48(88.9)	14(93.3)
肝硬化[例(%)]	27(90.0)	36(66.7)	12(80.0)	5.891^b	0.053
KPS评分(x±s, 分)	91.7±4.6	89.6±6.7	88.0±6.8	2.048^a	0.143
肿瘤最大径(x±s, cm)	4.3±3.0	5.0±3.3	5.2±2.0	0.646^a	0.567
肿瘤数目[例(%)]				0.717^b	0.699
单发	14(46.7)	28(51.9)	6(40.0)
多发性	16(53.3)	26(48.1)	9(60.0)
远处转移[例(%)]				2.550^b	0.279
无	26(86.7)	41(75.9)	10(66.7)
有	4(13.3)	13(24.1)	5(33.3)
Child-Pugh分级[例(%)]				0.256^b	0.870
A	27(90.0)	48(88.9)	14(93.3)
B	3(10.0)	6(11.1)	1(6.7)
注：^a为F值，^b为χ²值。

下载: 导出CSV

表 2 3组中晚期HCC患者OS影响因素的Cox回归分析

Table 2. Cox regression analysis of overall survival and prognosis of three groups in patients with advanced HCC

项目	B	SE	Wald χ²	P值	HR(95% CI)
年龄	-0.341	0.212	1.231	0.762	1.012(0.652~1.346)
性别	0.433	0.181	1.872	0.673	0.983(0.762~1.454)
病灶大小	0.568	0.118	2.430	0.080	1.219(0.889~2.718)
转移	0.272	0.032	8.228	0.028	1.538(1.262~2.214)
WBC	0.215	0.121	1.212	0.539	1.112(0.778~1.977)
TBA	0.318	0.204	1.080	0.777	0.882(0.652~1.761)
TACE-RFA时间间隔	0.408	0.178	1.981	0.211	0.789(0.628~1.651)

下载: 导出CSV

参考文献(15)

[1]	YUN X, MENG H, ZHOU A F, et al. Efficacy of transcatheter arterial chemoembolization combined with capecitabine and cetuximab in the treatment of colorectal cancer with liver metastasis[J]. J BUON, 2021, 26(3): 1002-1008.
[2]	HIROOKA M, HIRAOKA A, OCHI H, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation: Outcomes in Patients with barcelona clinic liver cancer stage B hepatocellular carcinoma[J]. AJR Am J Roentgenol, 2018, 210(4): 891-898. doi: 10.2214/AJR.17.18177
[3]	LIU L, LIANG X X, XU X X, et al. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer[J]. Acta Biomater, 2021, 130: 374-384. doi: 10.1016/j.actbio.2021.05.031
[4]	SUN M, SHANG P Y, BAI J T, et al. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer[J]. J Clin Lab Anal, 2021, 35(2): e23633. DOI: 10.1002/jcla.23633
[5]	HAN T, YANG X D, ZHANG Y, et al. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis[J]. Biosci Trends, 2019, 13(5): 374-381. doi: 10.5582/bst.2019.01153
[6]	《原发性肝癌诊疗规范(年版)》编写专家委员会. 原发性肝癌诊疗规范(2019年版)[J]. 中国临床医学, 2020, 27(1): 140-156. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202002001.htm Expert Committee for the compilation of the standard for diagnosis and treatment of primary liver cancer (EDITION) Standard for diagnosis and treatment of primary liver cancer (2019 Edition)[J]. Chinese Journal of Clinical Medicine, 2020, 27(1): 140-156. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202002001.htm
[7]	CHOE W H, KIM Y J, PARK H S, et al. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(35): 12588-12594. doi: 10.3748/wjg.v20.i35.12588
[8]	SOHN W, CHOI M S, CHO J Y, et al. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: Long-term outcomes and predictive factors[J]. Gut Liver, 2014, 8(5): 543-551. doi: 10.5009/gnl13356
[9]	ZHAO M, WANG J P, PAN C C, et al. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement[J]. Eur J Radiol, 2012, 81(10): 2717-2725. doi: 10.1016/j.ejrad.2011.10.023
[10]	朱德东, 石小军, 王哲, 等. 射频消融联合肝动脉化疗栓塞对大肝癌患者机体抗肿瘤免疫状态的影响[J]. 中华全科医学, 2018, 16(1): 38-40. doi: 10.16766/j.cnki.issn.1674-4152.000010 ZHU D D, SHI X J, WANG J, et al. Effect of radiofrequency ablation combined transcatheter arterial chemoembolization on antitumor immune status of patients with hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2018, 16(1): 38-40. doi: 10.16766/j.cnki.issn.1674-4152.000010
[11]	应希慧, 张登科, 陈丽, 等. 放射性粒子植入在原发性肝癌射频消融后应用人群的初步探讨[J]. 中华医学杂志, 2020, 100(17): 1310-1314. doi: 10.3760/cma.j.cn112137-20200225-00447 YING X H, ZHANG D K, CHEN L, et al. Differential population screening and efficacy analysis of 125I implantation after radiofrequency ablation of primary liver cancer[J]. National Medical Journal of China, 2020, 100(17): 1310-1314. doi: 10.3760/cma.j.cn112137-20200225-00447
[12]	杨晓珍, 张晓勇, 刘海春, 等. 肝动脉化疗栓塞联合射频消融治疗肝癌疗效及预后分析[J]. 中国基层医药, 2016, 23(17): 2609-2612. doi: 10.3760/cma.j.issn.1008-6706.2016.17.013 YANG X Z, ZHANG X Y, LIU H C, et al. The curative effect and prognostic analysis of transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of liver cancer[J]. Chinese Journal of Primary Medicine and Pharmacy, 2016, 23(17): 2609-2612. doi: 10.3760/cma.j.issn.1008-6706.2016.17.013
[13]	YIN X, ZHANG L, WANG Y H, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma[J]. BMC Cancer, 2014, 14: 849. doi: 10.1186/1471-2407-14-849
[14]	TANAKA M, ANDO E, SIMOSE S, et al. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma[J]. Hepatol Res, 2014, 44(2): 194-200. doi: 10.1111/hepr.12100
[15]	JIN J, ZHOU T Y, LOU J Y, et al. Efficacy of licartin combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced primary liver cancer[J]. J BUON, 2020, 25(6): 2584-2591.